B
Bull
Bull · 25%VYGR
$5.47
Scenario price
$1.720
-0.138 (-8.02%)At close
Loading chart…
- High
- 1.880
- Open
- 1.870
- VWAP
- 1.76
- Volume
- 1.31M
- Mkt Cap
- 427.53M
- Low
- 1.680
- Amount
- 2.30M
- EV/EBITDA, TTM
- -0.29
Voyager Therapeutics, Inc. is a biotechnology company engaged in leveraging the power of human genetics to modify the course of neurological diseases. The Company’s pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of its programs are derived from its Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER) adeno-associated virus (AAV) capsid discovery platform, which is used to generate capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs includes Anti-Tau Antibody (VY7523), Tau Silencing Gene Therapy (VY1706), SOD1 Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program and others.
AI analysis of Voyager Therapeutics Inc (VYGR)
HoldVoyager Therapeutics Inc (VYGR) is currently trading at $1.78, which is close to its 52-week low of $1.68. The stock has seen a significant decline of 55.83% year-to-date, indicating a challenging market environment. The RSI is at 39.49, suggesting that the stock is nearing oversold territory, which could indicate a potential reversal in price. However, the forward P/E ratio is 8.44, which is relatively low compared to industry standards, hinting at potential undervaluation. The main risk is the negative net income, which was reported at -$27.9 million for Q1 2026, indicating ongoing financial struggles. Therefore, while there are some indicators of potential recovery, the overall financial performance and recent price history suggest that it may be prudent to hold rather than buy at this time.
Analyst Ratings (10)
+667.44% upside
Buy
9 Buy
1 Hold
0 Sell
Current: 1.72
Low
8.00
Average
13.20
High
25.00
Morgan Stanley
Equal Weight
$39
2026-01-16
Morgan Stanley
2026-01-16
Price Target
$39
Equal Weight
H.C. Wainwright
Buy
$25
2025-11-12
H.C. Wainwright
2025-11-12
Price Target
$25
Buy
HC Wainwright & Co.
Strong Buy
$30
2025-04-08
HC Wainwright & Co.
2025-04-08
Price Target
$30
Strong Buy
HC Wainwright & Co.
Strong Buy
$30
2025-03-13
HC Wainwright & Co.
2025-03-13
Price Target
$30
Strong Buy
Canaccord Genuity
Strong Buy
$12
2025-03-13
Canaccord Genuity
2025-03-13
Price Target
$12
Strong Buy
Valuation Metrics
The current forward P/E ratio for Voyager Therapeutics Inc (VYGR) is 8.44, compared to its 5-year average forward P/E of -1.75.
Alphio AI Price Scenarios for VYGR
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding VYGR
Events Timeline
News
9.006-02NASDAQ.COMFDA Clears IND for Voyager's VY1706 Alzheimer's Gene Therapy
9.006-01NewsfilterVoyager Therapeutics Receives FDA Approval for Alzheimer's Clinical Trial
- 9.005-13Newsfilter
VY1706 IND Application on Track for Q2 2026 with Promising Data
9.505-07seekingalphaVoyager Therapeutics Q1 Financial Results Analysis
9.005-07seekingalphaFDA Grants Orphan Drug Designation to Neurocrine's NBIB-223
VYGR FAQ — answered by Alphio AI
Voyager Therapeutics, Inc. is a biotechnology company engaged in leveraging the power of human genetics to modify the course of neurological diseases. The Company’s pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of its programs are derived from its Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER) adeno-associated virus (AAV) capsid discovery platform, which is used to generate capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs includes Anti-Tau Antibody (VY7523), Tau Silencing Gene Therapy (VY1706), SOD1 Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program and others. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Voyager Therapeutics Inc (VYGR) is currently trading at $1.78, which is close to its 52-week low of $1.68. The stock has seen a significant decline of 55.83% year-to-date, indicating a challenging market environment. The RSI is at 39.49, suggesting that the stock is nearing oversold territory, which could indicate a potential reversal in price. However, the forward P/E ratio is 8.44, which is relatively low compared to industry standards, hinting at potential undervaluation. The main risk is the negative net income, which was reported at -$27.9 million for Q1 2026, indicating ongoing financial struggles. Therefore, while there are some indicators of potential recovery, the overall financial performance and recent price history suggest that it may be prudent to hold rather than buy at this time.
10 analysts cover VYGR: 9 rate it Buy, 1 Hold and 0 Sell. The average price target is 13.20.
Community
More ↗No posts yet
Sign up or log in to join the discussionRelated articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.